Erschienen in:
01.12.2007 | Lab. Investigation-Human/Animal Tissue
No association of MDM2 SNP309 with risk of glioblastoma and prognosis
verfasst von:
Soufiane El Hallani, Yannick Marie, Ahmed Idbaih, Mathieu Rodero, Blandine Boisselier, Florence Laigle-Donadey, François Ducray, Jean-Yves Delattre, Marc Sanson
Erschienen in:
Journal of Neuro-Oncology
|
Ausgabe 3/2007
Einloggen, um Zugang zu erhalten
Abstract
The MDM2 SNP309 variant has been shown to increase MDM2 expression and to be associated with tumor formation. In glioblastomas, the P53/MDM2 pathway is of crucial importance and MDM2 amplification is related to poor prognosis. However, we show here that MDM2 SNP309 is not associated with glioblastoma risk, and is not a prognostic factor.